Drugs / V221
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00092430 | Sep 2002 → Jun 2003 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00975507 | Mar 1998 → Jan 1999 | measles, mumps infectious disease, rubella, varicella zoster infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V221 | “This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.” NCT00975507 ↗ |
| Known as | ProQuad | “frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).” PMID 17502347 ↗ May 2007 |
| Modality | Vaccine | “virus vaccine live” NCT00092430 ↗ |
| Route | Subcutaneous | “a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90” NCT00975507 ↗ |